dataesr/scientific-paragraphs-categorization huggingface dataset:
2. The responses of the three detectors are reported in Figure  5. The obtained results confirm the hypothesis that reducing the overall detector series resistance results in an improved linearity range. In particular, the response of both the prototypes with higher boron concentration in the p-type layer start saturating at about 1. 2 Gy/pulse, the deviation from linearity at higher DPPs being definitively more pronounced in the DD-P + sample. A specific detector layout was then chosen in order to combine the positive effects observed in both the above reported systematic investigations. In particular, two fD prototypes were fabricated (fD-A and fD-B), both with a F I G U R E 6 Dose per pulse (DPPs) measured by the fD-A prototype at SIT. The three datasets refer to the measurements performed by: the UNIDOS E electrometer alone (blue triangles), the UNIDOS E equipped with the external capacitance box (black squares), and the Keithley 6517B electrometer (red triangles).
It's worth noting that such an effect was not observed in the previous plots due to the "early" saturation of the prototype response. This issue was overcome by adopting the external capacitance box provided by PTW. In fact, the experimental data obtained by the UNIDOS E in this modified setup (UNIDOS E + box in Figure  6 ) are found to be fully consistent with those obtained by the Keithley 6517B electrometer. As far as the response of the fD-A detector is concerned, it is found to be linear up to a DPP of 10. 4 Gy/pulse, that is the maximum value achievable by using the 40 mm applicator. This finding clearly confirms the physical hypothesis of the present systematic F I G U R E 7 Dose per pulse (DPPs) measured by the fD-B prototype at the Curie Institute. The dashed line with slope 1 is reported to evaluate the deviation from linearity of the detector response investigation as well as the effectiveness of the changes made in the diamond detector design and layout.
I G R E 8 (a) Percentage depth dose (PDD) measurements by the fD-B prototype at Curie Institute. The three datasets refer to the measurements performed by using the 120, 40, and 30 mm applicators, characterized by a dose per pulse (DPP) values at d max of 3. 5, 17. 2, and 20. 6 Gy/pulse, respectively. (b) Difference plot between the PDDs measured by using the 40 and 30 mm applicators and the one measured by the 120 mm applicator (black and red symbols, respectively).
F I G R E 8 (a) Percentage depth dose (PDD) measurements by the fD-B prototype at Curie Institute. The three datasets refer to the measurements performed by using the 120, 40, and 30 mm applicators, characterized by a dose per pulse (DPP) values at d max of 3. 5, 17. 2, and 20. 6 Gy/pulse, respectively. (b) Difference plot between the PDDs measured by using the 40 and 30 mm applicators and the one measured by the 120 mm applicator (black and red symbols, respectively).
ICEMR studies are now utilizing these barcodes in PNG and Cambodia (Asia Pacific ICEMR), in addition to Mali (West Africa ICEMR). Whole genome sequencing is also being conducted in the three countries to validate SNP barcodes and confirm patterns observed. Using ICEMR samples to monitor the evolution of antimalarial drug resistance mutations is a major goal of the program. Recently, kelch13 C580Y mutations associated with artemisinin were discovered for the first time in PNG by genotyping P. falciparum isolates collected from Wewak, East Sepik Province in 2016. 50 Although the genomic data were consistent with kelch 13 C580Y emerging in the local parasite population, it was not clear whether it emerged in PNG, West Papua, or another nearby location. We recently developed a multiplex amplicon sequencing assay known as "DResCode" that targets well-known drug resistance genes (kelch13, crt, mdr1, dhfr, dhps, mrp1) in addition to a PNG genetic background that is associated with the kelch13 C580Y mutation.
AI129392-01 ). The South- West Pacific ICEMR program  ( 2010-2017 ) was funded by the  NIH  (grant  U19 AI089686 ). L. J. R. ( GNT1161627 ), S. K. ( GNT1141441 ), and I. M ( GNT1155075 ) are supported by  Australian Government National Health and Medical Research Council Fellowships. J. G. B. was supported by a  National Health and Medical Research Council (NHMRC)   Investigator Grant  ( 1173046 ) L. R. , M. L. , and I. M. are supported by the  NHMRC Australian Centre for Research Excellence in Malaria Elimination. Authors' addresses:  Jerrome Ateudjieu ,  Sonia Sonkeng Nafack ,  Ketina Hirma Tchio-Nighie ,  Herve Tchokomeni ,  Landry Beyala Bita 'a,  Paul Ntsekendio Nyibio ,  Etienne Guenou ,  Kedia Mayah Mondung ,  Frank Forex  and  Kiadjieu Dieumo ,  MA SANTE, Public Health, Yaounde, Cambodia , E-mail: jateudjieu@masante-cam.
NU-AGE The NU-AGE trial was conducted in five European study centres (Clermont Ferrand in France, Bologna in Italy, Wageningen in the Netherlands, Warsaw in Poland and Norwich in the UK). In total, 1296 participants were included, of which n = 1245 had sufficient data to be included in the current analysis. A complete overview of the study protocol is presented in previous papers. 8, 12 In brief, NU-AGE included adults aged 65-79 years who were living independently, were non-frail and non-malnourished and were free of dementia, major chronic diseases and diabetes. The NU-AGE trial was a 1-year intervention with a Mediterranean-style diet designed to meet the nutritional needs of older adults. As this intervention was not aiming at increasing protein intake, we only used the baseline data for the analyses presented in this paper.
ProMO The intervention trial ProMO (n = 82) included adults aged 65 years and above who were (at risk of being) malnourished. The full protocol of the trial has been described elsewhere. 9 he trial excluded those with an expected life expectancy of <12 months, performing over 2 h/week of resistance exercise, impaired kidney function, lactose intolerance or milk protein allergy and those who used corticosteroids (unless administered via inhaler or topically) or diabetes medications. Nutritional intake was assessed by 2-day food records on consecutive days. Trained dietitians interviewed participants to maximize record completeness and to estimate portion sizes by using household measures. Food records were calculated into nutrients by using the Dutch Food Consumption Database 2011. 13 DXA, performed by trained research assistants, was used to assess BMD (Lunar Prodigy Advance; GE Health Care, Madison, WI).
ProMuscle The ProMuscle intervention included 127 frail or pre-frail adults aged 65 years and above. 10, 19 The trial excluded participants who were involved in resistance exercise training programmes in the 2 years prior to screening, who were diagnosed with chronic obstructive pulmonary disease (COPD), renal insufficiency, diabetes or cancer. Dietary intake assessment was carried out via 3-day food records (one random weekday plus both weekend days). Trained dietitians discussed food records with participants and made use of household measures to estimate portion sizes. Foods were calculated into nutrients by using the Dutch Food Consumption Database of 2006. 20 BMD was assessed by DXA (Lunar Prodigy Advance; GE Health Care, Madison, WI). The ProMuscle intervention consisted of four arms: placebo, protein, exercise and protein + exercise.
Nutrient intake was calculated by using the Dutch Food Consumption Database 2011. 13 BMD was assessed via DXA (Lunar Prodigy Advance, GE Health Care, Madison, WI), which was operated by trained research assistants. The PiP intervention consisted of protein + exercise. The protein intervention aimed to increase protein intake during each main meal moment to at least 25 g. Based on the food record, a dietitian gave tailored advice to each participant in the intervention group. No protein supplements were usedthe protein intake was increased via protein-rich dairy products, such as yoghurt, quark and cheese. Progressive resistance exercise sessions (twice a week, 1 h per session) were supervised by physiotherapists. During the first 12 weeks of the intervention, participants were supervised intensively and received protein-rich products for free.
For this analysis, we applied a variant on the third model in which we omit adjustment for calcium intake and vitamin D intake. Lastly, the ratio of animal protein to plant protein intake was divided in tertiles and evaluated with the third model as well. All cross-sectional analyses were carried out in SPSS 25 (IBM Corp. , Armonk, NY, USA), and graphs and figures were created using GraphPad Prism 5 (GraphPad Software Inc. , San Diego, CA, USA). Alpha was set at 5%. The effects of protein or protein and exercise interventions versus control were analysed by using linear mixed models. Models were built with fixed effects for time, treatment, time*treatment, sex and age. Random effects were used to model subject-specific intercepts nested within the study these subjects participated in. Post hoc testing for differences between fixed effects was adjusted by Bonferroni correction.
Amplicons from targeted sequences were generated using nested PCR assays as previously described  [40, 41]  and sent to Eurofins (Germany) for sequencing. Mutations at codons 440-680 for Pfkelch13, at codons  72-76, 93, 97, 145, 218, 343, 350 and 353  for Pfcrt, at codons 86, 184, 1034, 1042 and 1246 for Pfmdr-1, at codons 51, 59, 108, 164 for Pfdhfr and at codons 436, 437, 540, 581, 613 for Pfdhps were assessed with the CLC Main Workbench 20 software (Qiagen). Electropherograms with mixed alleles were considered as mutant for the purpose of mutation frequency estimation. Quality control was assessed by including blinded quality control samples (parasites with wild-type, C580Y and R539T alleles for Pfkelch13 and 3D7, Dd2, 7G8 laboratory strains for Pfdhfr, Pfdhps, Pfcrt and Pfmdr-1) in each 96-well sequencing plate.
Sample size and data management A minimum sample of 73 children per site was estimated based on a 5% treatment failure rate for ASAQ and AL and with a 95% confidence level and 5% precision. Twenty percent (n = 15) was added to account for loss to followup and withdrawal during the 28-day follow-up period. The final target sample was 88 per site. Data were doubleentered, validated against the case sheet in case of discrepancies, and analysed using the WHO excel software programme (http:// www. who. int/ malar ia/ publi catio ns/ atoz/ 97892 41597 531/ en/). Per-protocol and Kaplan-Meier analyses were used to analyse treatment outcomes according to the WHO protocol  [36]. The per-protocol analysis was performed excluding patients who discontinued treatment, stopped treatment, withdrawn, or had new infections during follow-up.
In the KM analysis, these cases were censored on the last day of follow-up, withdrawal, or re-infection. Recurrent cases with indeterminate PCR results were excluded from both the perprotocol and KM analyses. Descriptive statistics including percentages, mean, standard deviation, and range were presented. Patient characteristics at the time of enrollment and treatment outcomes were compared between sites within each study drug. Chi-square and Fisher exact tests were used to compare categorical data and t-tests were used to compare continuous variables. The presence of Pfcrt K76T, Pfmdr1 N86Y andY184F mutations was compared between day 0 samples from cured and recrudescent patients using Fisher's exact test and an estimation of relative risk. A difference is considered significant if the p-value < is 0.
Markers for piperaquine resistance Estimation of Pfpm2 copy number was performed on 112 randomly selected day-0 samples (25% of day-0 samples per site). Interpretable data were obtained for 100 samples (89. 3%). Samples that were not interpretable were likely samples with insufficient DNA quantity (due to  initial parasite density) or poor DNA quality. Parasites in all samples carried a single copy of the Pfpm2 gene (CNV < 1. 5).
Acknowledgements The authors thank the parents or guardians of the study children who participated in the study. They thank the health workers at the study health facilities who helped conduct the study. The authors also thank the  Global Fund  to Fight HIV/AIDS,  TB and Malaria (GFATM)  for providing the financial support, and the  Bill and Melinda Gates Foundation  for their financial support through the  World Health Organization in Geneva. This work used the computational and storage services (TARS cluster) provided by the  IT department at Institut Pasteur and the Biomics Platform ,  C2RT ,  Institut Pasteur, Paris, France , (supported by  France Génomique ,  ANR-10-INBS-09  and IBISA).
Funding Funding was obtained from the  GFATM, Bill and Melinda Gates Foundation  through  WHO  (grant no. OPP1140599 ). This work was also supported by the  French Government (Agence Nationale de la Recherche )  Investissement d' Avenir programme, Laboratoire d'Exceellence (LabEx)  " Frech Parasitology Alliance For Health Care " ( ANR-11-LABX-0024-PARAFRAP ).
Two conditions were evaluated: "firm" (standing on the force plate) and "foam" (Physiopad®; 50x41x5cm; 52 kg/m 3 ). Four muscle vibrators (VB115, Techno Concept, France) were placed bilaterally on the triceps surae (TS) and the lumbar paravertebral muscles (LPM). Vibration frequency was set at 80 Hz with an amplitude of 0. 5 mm to stimulate the muscle spindles  [29]. To avoid a learning effect  [28] , computer software automatically and randomly triggered the vibrators. This also ensured that neither the participant nor the experimenter could anticipate the next site of vibration. Each trial lasted for 50 s. Recordings began 10 s prior to vibration ("PRE"), vibration was applied for 20 s ("VIB") and the recording continued for another 20 s during the re-stabilization period ("POST"). Electromyographic (EMG) activity was recorded from three muscles of the dominant limb (i.
e. the preferred push-off limb) using surface electrodes positioned by the same experimenter according to the surface EMG for non-invasive assessment of muscles (SENIAM) guideline  [30] , after the skin was shaved and cleaned. We evaluated the gluteus medius (GM) and semi tendinous (ST) because sub-optimal activity of these muscles is related to the risk ACL injury  [16] , and fibularis longus (FL) because it plays an important role in postural control on different surfaces  [31]. A force platform (AMTI, model BMS464508, Watertown, MA, 1000 Hz) connected to a measurement card (PCIM-DAS16 card, measurement computing, A/D conversion 16bits) was used to record centre of pressure (CoP) displacement. Signals were stored for subsequent analysis using DColl software (GRAME, Laval University, Quebec, Canada) and filtered using a Butterwoth low-pass, fourth order filter with a cut-off frequency of 10 Hz.
Anterior/Posterior centre of pressure displacement (dCoP) and velocity (vCoP) were calculated using custom software developed in Matlab (GRAME, Laval University, Quebec, Canada). EMG signals were recorded with pre-amplified electrodes (type SX230-1000, Biometrics Ltd, Newport, UK, 1000 Hz) placed 2 cm apart on the muscle bellies. The EMG signal was band-pass filtered (15-450 Hz) close to the recording site. We analysed variables that have been shown to be the most reliable indicators of the response to muscle vibration for the evaluation of proprioceptive weighting and balance recovery  [28]. Relative Proprioceptive Weighting (RPw) is the ratio between the effects of vibration of the TS and the LPM (absolute TS/(absolute TS + absolute LPM)) on CoP displacement (dRP W ) and velocity (vRP W ).
Study Design This was a phase 3, randomized, open-label, parallel group, active-controlled study conducted at 24 centers in China (NCT03232281; study funded by Ipsen). Patients were randomized 1:1 (allocation through an interactive web response system) to receive a total of two intramuscular injections with triptorelin pamoate PR 3-month (15 mg, once every 12 weeks) or a total of six intramuscular injections with triptorelin acetate PR 1-month (3. 75 mg, once every 4 weeks) (Fig. 1 ). The study comprised a screening period of up to 5 weeks, a 24-week treatment period, and a follow-up period up to week 40 or until the recovery of menses, whichever occurred first. The visit and dosing schedules are shown in Fig. S1. The first dose was given at baseline (day 1), which occurred in the patient's follicular phase (first to fifth day of menses).
Statistical Analyses A sample size of 300 (150 patients per group) was planned to ensure adequate precision and confidence in outcome estimates, based on previous study data  [19]. Assuming that the proportion of patients chemically castrated at week 12 with triptorelin acetate PR 1-month would be no less than 92%, a sample size of 133 patients per treatment group was estimated to provide 85% power to demonstrate the noninferiority objective, with participant attrition estimated as 10%. Analysis of efficacy objectives was conducted on the full analysis set (FAS), including all randomized patients receiving at least one treatment dose, and with at least one baseline and post-baseline primary endpoint assessment. The primary efficacy analysis was performed on the per-protocol (PP) set, including all patients in the FAS with a primary endpoint measurement at week 12 and without major protocol deviations.
Changes in endometriosis-associated pelvic pain and serum E2, LH, and FSH concentrations were presented using summary statistics; 95% CIs for the difference in mean values and change from baseline were calculated using a linear model for repeated measurements, adjusting for treatment group and its interaction, with visit and randomization as stratification factors. Median time to menses recovery, 25th and 75th quartile times, and 95% CIs were estimated using the Kaplan-Meier method. Patient demographics and baseline characteristics, and safety endpoints were analyzed using descriptive statistics. Statistical evaluations were performed using Statistical Analysis System (SAS) Ò software (version 9. 4). The noncompartmental analysis was performed using SAS software on the PK data collected for the PK/PD subgroup to assess the individual PK parameters for both formulations.
Pharmacokinetic and Pharmacodynamic Analyses The final PK data set comprised 299 patients, of whom 149 received triptorelin pamoate PR 3-month and 150 received triptorelin acetate PR Treatment-related serious TEAEs 0 1 (0. 7) [1] 1 (0. 3) [1] TEAEs leading to withdrawal 1 (0. 7 ) [1] 1 (0. 7) [1] 2 (0. 7) [2] TEAEs leading to treatment interruption 0 0 0 Serious TEAEs leading to treatment withdrawal 0 0 0 Serious TEAEs leading to treatment interruption 0 0 0 TEAEs leading to death 0 0 0 [E] number of events, MedDRA Medical Dictionary for Regulatory Activities, PR prolonged-release, TEAE treatmentemergent adverse event Note: if a patient experienced more than one event in a category, the patient was counted only once in that category. MedDRA version 22. 1 A list of TEAEs reported in 5% or more of patients in either treatment arm is reported in Table  S5  1-month.
All patients provided written informed consent before study entry. Data Availability. The datasets generated during and/or analyzed during the current study may be available on reasonable request. Where patient data can be anonymized, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen. com and will be assessed by a scientific review board. Data are available beginning 6 months and ending 5 years after publication; after this time, only raw data may be available. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.
Methods: We conducted spatial analyses for the 18 most frequent cancer sites, using data collected by the population-based cancer registry of Guadeloupe over the period 2008-2017. For each cancer sites, we used the Besag, York and Mollié model to estimate smoothed standardized incidence ratios (SIRs) at a sub-municipality level. In addition, we performed ascendant hierarchical clustering of these smoothed SIRs to describe the relationship between the different cancer sites and to identify geographical clusters.
Data We used data from the Guadeloupe cancer registry, which collects all new cancer cases of patients residing in Guadeloupe since 2008. The registry routinely collects for all cancer sites: the date of diagnosis, the topographical and morphological codes of the International Classification of Diseases for Oncology, (ICD-O3) and sociodemographic data (sex, date of birth and exact address of the place of residence). The registry belongs to the French Network of Cancer Registries (FRANCIM) and meets high quality criteria; the completeness and data quality are regularly assessed by the "Comité d'évaluation des registres" (CER). We conducted spatial analysis for the.
D2) in the hclust function of R stats package  [11]. Two AHCs were performed  [2]. First, in order to highlight the relationships between the incidence of different cancers, we performed an AHC of the 18 cancer sites. We also calculated Spearman's correlation coefficients between the smoothed SIRs. Then, we performed an AHC of the 136 IRIS in order to define geographical clusters. The optimal number of clusters was determined with the elbow method using total within-cluster sum of square as criterion and from examination of the clustering dendrogram.
Ongoing Trials Anakinra is the recombinant form of the naturally occurring interleukin 1α (IL-1Rα) and blocks the activity of both IL-1α and IL-1β. The Anakinra vs. Placebo for the Treatment of Acute Myocarditis (ARAMIS) trial (ClinicalTrials. gov identifier: NCT03018834) is a double-blind randomized clinical trial testing the superiority of anakinra in addition to standard of care, defined as the maximum tolerated dosage of any beta-blockers and angiotensin receptor blockade in acute myocarditis. The ARAMIS trial has completed the randomization phase and will directly assess the role of the IL-1 immune innate pathway in the setting of AM. The rationale of blocking the (IL-1β) pathway in myocarditis relies on prior studies that suggested the central role of the Nucleotide-binding domain  (NACHT)  and Leucine-rich repeat (LRR) and Pyrin domain (PYD) (NLR) containing protein 3 (NLRP3) inflammasome predominately expressed in macrophages  (43) (44) (45).
This trial has also a sub-study that has assessed ACE-i continuation or discontinuation after 1 month in patients with normal LVEF that are followed for 1 year. This trial excluded the patients with the poorest outcome, specifically those on mechanical ventilation or temporary mechanical circulatory supports (t-MCS). To address specifically patients with FM or acute HF the MYocarditis THerapy with Steroids (MYTHS) trial (ClinicalTrials. gov identifier: NCT05150704) will randomize 288 patients with FM (need for inotropes and/or t-MCS) or AM complicated by HF and severely impaired LVEF (<41%) to pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days) on top of standard therapy and maximal supportive care vs. placebo (Figure  2 ). The combined primary endpoint is defined as the time from randomization to the first event occurring within 6 months including (1) all-cause death, or (2) HTx, or (3) long-term left-ventricular assistance device (LVAD) implant, or (4) need for an upgrading of the t-MCS, or (5) a ventricular tachycardia (VT)/fibrillation (VF) treated with direct current (DC) shock (excluding VT/VF in patients on t-MCS other than intra-aortic balloon pump [IABP]), or  (6)  first rehospitalization due to HF or VA, or advanced AVB.